Evidence map›Paper›PMID 29746173›Full record

ArticleAmerican journal of physiology. Gastrointestinal and liver physiology2018

Induction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24.

Geeta Rao, Hailey Houson, Gregory Nkepang, Hooman Yari, Chengwen Teng, Vibhudutta Awasthi

Open access · bronzeAbstract read
In one paragraph

Article in American journal of physiology. Gastrointestinal and liver physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Geeta RaoDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center , Oklahoma City, Oklahoma.
Hailey HousonDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center , Oklahoma City, Oklahoma.
Gregory NkepangDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center , Oklahoma City, Oklahoma.
Hooman YariDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center , Oklahoma City, Oklahoma.
Chengwen TengDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center , Oklahoma City, Oklahoma.
Vibhudutta AwasthiDepartment of Pharmaceutical Sciences, University of Oklahoma Health Science Center , Oklahoma City, Oklahoma.
University of Oklahoma Health Sciences Center · US

Funding

Biologic Evaluation of Liposome-Encapsulated HemoglobinR01HL104286 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI AWASTHI, VIBHUDUTTA · 2011 to 2014
$1.5M
NHLBI NIH HHS R01 HL104286
6 · The paper itself

Abstract

Multiorgan failure in hemorrhagic shock is triggered by gut barrier dysfunction and consequent systemic infiltration of proinflammatory factors. Our previous study has shown that diphenyldihaloketone drugs 4-[3,5-bis[(2-chlorophenyl)methylene]-4-oxo-1-piperidinyl]-4-oxo-2-butenoic acid (CLEFMA) and 3,5-bis[(2-fluorophenyl)methylene]-4-piperidinone (EF24) restore gut barrier dysfunction and reduce systemic inflammatory response in hemorrhagic shock. We investigated the effect of hemorrhagic shock on proteasome activity of intestinal epithelium and how CLEFMA and EF24 treatments modulate proteasome function in hemorrhagic shock. CLEFMA or EF24 (0.4 mg/kg) were given 1 h after withdrawing 50% of blood from Sprague-Dawley rats; no other resuscitation was provided. After another 5 h of compensation, small gut was collected to process tissue for proteasome activity, immunoblotting, and mRNA levels of genes responsible for unfolded-protein response (XBP1, ATF4, glucose-regulated protein of 78/95 kDa, and growth arrest and DNA damage inducible genes 153/34), polyubiquitin B and C, and immunoproteasome subunits β type-8 and -10 and proteasome activator subunit 1. We found that hemorrhagic shock induced proteasome activity in gut tissue and reduced the amounts of ubiquitinated proteins displayed on antiubiquitin immunoblots. However, simultaneous induction of unfolded-protein response or immunoproteasome genes was not observed. CLEFMA and EF24 treatments abolished the hemorrhagic shock-induced increase in proteasome activity. Further investigations revealed that the induction of proteasome in hemorrhagic shock is associated with disassembly of 26S proteasome; CLEFMA and EF24 prevented this disassembly. Consistent with these data, CLEFMA and EF24 reduced hemorrhagic shock-induced degradation of 20S substrate ornithine decarboxylase in gut tissue. These results suggest that activated proteasome plays an important role in ischemic gut pathophysiology, and it can be a druggable target in shock-induced gut dysfunction. NEW & NOTEWORTHY Ischemic injury to the gut is a trigger for the systemic inflammatory response and multiple organ failure in trauma and hemorrhagic shock. We show for the first time that hemorrhagic shock induces the gut proteasome activity by engendering 26S proteasome disassembly. Diphenyldihaloketones 4-[3,5-bis[(2-chlorophenyl)methylene]-4-oxo-1-piperidinyl]-4-oxo-2-butenoic acid and 3,5-bis[(2-fluorophenyl)methylene]-4-piperidinone treatment prevented the 26S disassembly. Understanding the role of proteasome in shock-associated gut injury will assist in the development of therapeutic means to address it.

Indexed as

Multiple Organ FailureShock, HemorrhagicSystemic Inflammatory Response SyndromeAnimalsAnti-Inflammatory AgentsBenzylidene CompoundsIntestinal MucosaIntestine, SmallPiperidonesProteasome Endopeptidase ComplexRatsTreatment Outcome3,5-bis(2-fluorobenzylidene)piperidin-4-one4-(3,5-bis(2-chlorobenzylidene)-4-oxopiperidine-1-yl)-4-oxo-2-butenoic acidAnti-Inflammatory AgentsATP dependent 26S proteaseBenzylidene CompoundsPiperidonesProteasome Endopeptidase ComplexCLEFMAEF24hemorrhagic shockproteasomesmall intestine

Identifiers

PMID29746173
PMCPMC6139642
OpenAlexW2802698756

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.